SCHEMBL13484145

SCHEMBL13484145

Nc1ncn(-c2ccc(F)c3c(C(=O)C(=O)N4CCN(C(=O)c5ccccc5)CC4)c[nH]c23)n1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 6/20 0.53
CYP2C9 P11712 5/20 0.53
CYP2D6 P10635 5/20 0.53
CYP3A4 P08684 3/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C8 P10632 1/20 0.53
CYP2B6 P20813 1/20 0.53
KCNH2 Q12809 1/20 0.53
KDM4E B2RXH2 1/20 0.38
ALOX15 P16050 1/20 0.38
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
KIT P10721 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
RAB9A P51151 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2629191 0.87 CYP2C19 (0.65) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL6441371 0.85 CYP3A4 (0.61) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL6441221 0.84 CYP2C9 (0.50) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL6445269 0.81 CYP2C9 (0.49) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL6442505 0.81 CYP2C9 (0.56) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL6442889 0.80 CYP2C9 (0.55) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL13484146 0.80 CYP2C19 (0.52) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL6445221 0.79 CYP2C9 (0.54) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL12215153 0.79 CYP2C9 (0.54) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL6443074 0.79 CYP2C9 (0.55) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662823-B2 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-16 US disclosed
US-7662823-B2 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-16 US disclosed